Research Signal – Source date 2025-12-08
A ClinicalTrials.gov record describes a planned phase 1 study of senolytic therapy for adults with secondary progressive multiple sclerosis. The study is designed to ask whether intermittent dasatinib and quercetin treatment is feasible and tolerable, while collecting early information about physical and thinking abilities and biological markers.
The supplied registry record lists the study as not yet recruiting, with an estimated enrollment of 30 people and no posted results. Its estimated start date is January 15, 2026. Those dates describe the plan; they do not establish that recruitment, treatment or follow-up had begun. The immediate question is therefore not whether senolytics have improved progressive MS, but whether this approach can be investigated safely and consistently enough to justify a more rigorous test.
The biological idea behind senolytic treatment
Senolytics are drugs intended to remove senescent cells, which are older or damaged cells that can remain active and release inflammatory signals. The investigators propose that these signals may contribute to chronic inflammation, nerve-fiber damage and impaired repair of myelin, the insulating material around nerve fibers, in progressive MS.
The combination being studied is dasatinib and quercetin, taken together as an experimental senolytic approach. The registry presents findings from an animal model of MS and observations from early studies of the combination in other age-related conditions as part of the rationale for the trial. Those observations explain why the investigators are testing the idea; they are not results from people with MS in this study.
The proposed chain is biologically plausible within the investigators’ hypothesis, but each step still needs to be tested in the target population. Removing senescent cells, changing inflammatory signals or shifting blood biomarkers would not automatically demonstrate that damaged nerves have repaired or that disability has been reversed.
Who the study is designed to include
The planned participants are adults aged 50 to 85 with secondary progressive MS whose symptoms have been getting worse and who are not currently taking a multiple sclerosis disease-modifying therapy. This is a restricted research population, not a general treatment recommendation.
Participants are scheduled to take 100 milligrams of dasatinib and 1,250 milligrams of quercetin by mouth once a day for two consecutive days every two weeks, over 12 consecutive weeks. Follow-up is planned through one year from enrollment so investigators can monitor treatment effects and adverse drug effects beyond the 12-week treatment period.
The intermittent schedule is part of what the study must show is workable in practice. It also gives the investigators a defined treatment period in which to assess whether participants can remain engaged with the visits and dosing plan.
What the first measurements are meant to establish
The listed primary outcomes focus on whether the study can function as intended. Retention means keeping participants through the three-month treatment period with no more than one missed study visit. Recruitment feasibility is the number of people screened to identify those who meet the eligibility requirements. Adverse drug effects are tracked from baseline through study completion at one year.
These practical measures come before any strong claim about benefit. The investigators also plan to collect preliminary information on physical and cognitive function, along with circulating markers related to senescence, neurodegeneration and the T-cell immune response. Such measurements may help determine whether the approach deserves a larger study, but blood-marker changes are not the same as demonstrated repair within the central nervous system.
Why the design leaves the main treatment question open
This is an open-label, single-group study. Participants and investigators will know that the treatment is being given, and the study does not include a randomized comparison group receiving another intervention or no study treatment. If physical or cognitive measures change, the design cannot by itself show how much of that change was caused by dasatinib and quercetin rather than by other influences.
The design is appropriate for an initial feasibility and safety-oriented investigation, especially for a treatment strategy that has not yet been studied in people with MS. It is not structured to establish efficacy. The absence of posted results also means the record supplies no participant evidence that the combination was tolerated, improved function or altered the proposed biological processes in this trial.
The investigators describe the study as groundwork for a future randomized controlled trial. Such a trial would be needed to test whether any apparent functional benefit exceeds what would have occurred without the treatment and whether the effect is meaningful to people living with progressive disease.
What targeting aging cells could mean for progressive MS
For older adults with secondary progressive MS, the potential patient consequence is an additional treatment approach aimed at improving physical and thinking abilities. That possibility depends first on acceptable adverse effects and reliable delivery, then on controlled evidence showing meaningful functional benefit.
This planned study is an initial step toward answering whether senolytic therapy is practical enough to move forward. Its value rests in clarifying feasibility, safety and early biological or functional signals, while a later randomized trial would determine whether targeting aging-related damaged cells can make a real difference in progressive MS.
Key Sources
- Primary source: Senolytics for Secondary Progressive MS
Government or Regulator · Clinical Trial · 2025-12-08
Keep exploring